Literature DB >> 28409248

[Radiotherapy for glioblastoma : ASCO endorses the ASTRO guideline].

Clemens Seidel1, Rolf-Dieter Kortmann2.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28409248     DOI: 10.1007/s00066-017-1132-y

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  8 in total

1.  Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.

Authors:  Annika Malmström; Bjørn Henning Grønberg; Christine Marosi; Roger Stupp; Didier Frappaz; Henrik Schultz; Ufuk Abacioglu; Björn Tavelin; Benoit Lhermitte; Monika E Hegi; Johan Rosell; Roger Henriksson
Journal:  Lancet Oncol       Date:  2012-08-08       Impact factor: 41.316

2.  International Atomic Energy Agency Randomized Phase III Study of Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme.

Authors:  Wilson Roa; Lucyna Kepka; Narendra Kumar; Valery Sinaika; Juliana Matiello; Darejan Lomidze; Dalenda Hentati; Douglas Guedes de Castro; Katarzyna Dyttus-Cebulok; Suzanne Drodge; Sunita Ghosh; Branislav Jeremić; Eduardo Rosenblatt; Elena Fidarova
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

3.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

5.  Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.

Authors:  Roger Stupp; Warren P Mason; Martin J van den Bent; Michael Weller; Barbara Fisher; Martin J B Taphoorn; Karl Belanger; Alba A Brandes; Christine Marosi; Ulrich Bogdahn; Jürgen Curschmann; Robert C Janzer; Samuel K Ludwin; Thierry Gorlia; Anouk Allgeier; Denis Lacombe; J Gregory Cairncross; Elizabeth Eisenhauer; René O Mirimanoff
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

6.  Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial.

Authors:  Ulrich Herrlinger; Niklas Schäfer; Joachim P Steinbach; Astrid Weyerbrock; Peter Hau; Roland Goldbrunner; Franziska Friedrich; Veit Rohde; Florian Ringel; Uwe Schlegel; Michael Sabel; Michael W Ronellenfitsch; Martin Uhl; Jaroslaw Maciaczyk; Stefan Grau; Oliver Schnell; Mathias Hänel; Dietmar Krex; Peter Vajkoczy; Rüdiger Gerlach; Rolf-Dieter Kortmann; Maximilian Mehdorn; Jochen Tüttenberg; Regine Mayer-Steinacker; Rainer Fietkau; Stefanie Brehmer; Frederic Mack; Moritz Stuplich; Sied Kebir; Ralf Kohnen; Elmar Dunkl; Barbara Leutgeb; Martin Proescholdt; Torsten Pietsch; Horst Urbach; Claus Belka; Walter Stummer; Martin Glas
Journal:  J Clin Oncol       Date:  2016-03-14       Impact factor: 44.544

7.  Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

Authors:  W Roa; P M A Brasher; G Bauman; M Anthes; E Bruera; A Chan; B Fisher; D Fulton; S Gulavita; C Hao; S Husain; A Murtha; K Petruk; D Stewart; P Tai; R Urtasun; J G Cairncross; P Forsyth
Journal:  J Clin Oncol       Date:  2004-03-29       Impact factor: 44.544

8.  Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.

Authors:  Roger Stupp; Sophie Taillibert; Andrew A Kanner; Santosh Kesari; David M Steinberg; Steven A Toms; Lynne P Taylor; Frank Lieberman; Antonio Silvani; Karen L Fink; Gene H Barnett; Jay-Jiguang Zhu; John W Henson; Herbert H Engelhard; Thomas C Chen; David D Tran; Jan Sroubek; Nam D Tran; Andreas F Hottinger; Joseph Landolfi; Rajiv Desai; Manuela Caroli; Yvonne Kew; Jerome Honnorat; Ahmed Idbaih; Eilon D Kirson; Uri Weinberg; Yoram Palti; Monika E Hegi; Zvi Ram
Journal:  JAMA       Date:  2015-12-15       Impact factor: 56.272

  8 in total
  1 in total

1.  Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning.

Authors:  Ann-Katrin Exeli; Daniel Kellner; Lukas Exeli; Phil Steininger; Frank Wolf; Felix Sedlmayer; Heinz Deutschmann
Journal:  Radiat Oncol       Date:  2018-02-06       Impact factor: 3.481

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.